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Advisor: Dr. Cyril L. Moore/Dr. Philip Needleman
Master of Science degree conferred July, 1981.
Thesis dated July 8, 1981
The use of acetylenic acid analogues differing in chain length or
position of the triple bond permitted the systematic study of structural
activity relationships for both the arachidonate metabolizing enzymes
(i.e., cyclooxygenase and lipoxygenase) in platelets and the relationship
of the enzyme to aggregation. Analogues were found that preferentially
inhibited: a) cyclooxygenase only; b) 12-lipoxygenase only (HETE);
c) both the cyclooxygenase and lipoxygenase; d) neither enzyme in plate
lets. There was a direct correlation between the rank order of potency
of the acetylenic analogues to inhibit platelet cyclooxygenase and to
suppress aggregation. Certain structural features of the triynoic
acetylenic analogues were critical in influencing platelet function;
thus, the presence of a triple bond at position 14 as well as the lack
of the triple bond at position 5 resulted in a compound that inhibited
both cyclooxygenase and platelet aggregation. Analogues that inhibited
the platelet 12-lipoxygenase but not the CO. were very weak inhibitors
of platelet aggregation. These acetylenic acid analogues provide poten
tially powerful tools for dissociating the two arachidonate metabolic
pathways and if other tissues are as readily manipulated as platelets,
iv
the analogues could be especially useful to gain insight into the contri
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Platelets contain two arachidonic acid metabolizing enzymes.
Cyclooxygenase converts arachidonate via prostaglandin (PG) endoperoxide
which is further metabolized to predominately thromboxane A2 (TxAj and
12-hydroxy-5,8,10-heptadecatrienoic acid (HHT). Small amounts of PGE2,
PGD2 and PGF2a are also formed as a result of the catabolism of arachi
donic acid in platelets. Lipoxygenase, the second arachidonic metaboliz
ing enzyme, yields 12-hydroperoxy-5,8,10,14-eicosatetraenoic acid (HPETE;
Hambert, M. et al^, 1974). The aqueous decay products of these arachi
donate metabolic pathways are thromboxane B2 (TxB£) and 12-hydroxy-
5,8,10,14-eicostetraenoic acid (HETE). The critical participation of
thromboxane A2 and PG-endoperoxides in platelet aggregation has fre
quently been demonstrated by Nugteren (1975), Hamberg and Samuelsson
(1974), and Hamberg (1975). Indeed, exogenous addition of thromboxane A£
will aggregate aspirin-treated platelets (Hamberg et al^, 1975). What
has remained elusive is the role of the lipoxygenase pathway in platelet
function. Inhibitors of the lipoxygenase pathway, such as the acetylenic
acid 5,8,n,14-eicosatetraynoic acid (ETYA; Hamberg, M. et £L_, 1974) or
BW755C (Higgs, G.A. et al^, 1979), also inhibited cyclooxygenase.
Recently several compounds have been described which preferentially
inhibit platelet lipoxygenase over the cyclooxygenase. Hammarstrbm et
iL. (1977) showed that 5,8,11-eicosatriynoic acid inhibited platelet
lipoxygenase preferentially over the platelet cyclooxygenase. Vanderhoek
et al^ (1980) reported that 15-hydroxy-5,8,ll ,14-eicosatetraenoic acid
selectively inhibited platelet lipoxygenase. Wilhelm et aK. (1981) and
Sun et aj_^ (1981) observed that the acetylenic analogues 4,7,10,13-ETYA
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and 5,8,11,14-heneicosatetraynoic acid inhibit platelet lipoxygenase at
concentrations that did not block TxA2 synthesis. However, the effects
of these compounds on platelet aggregation were not extensively analyzed.
Such experiments seem particularly pertinent since Dutilh et ail^ (1978,
1981) reported that low concentrations of ETYA block platelet lipoxygen
ase and not cyclooxygenase and, simultaneously, reverse arachidonate
induced aggregation. They concluded that the lipoxygenase is essential
for blood platelet aggregation.
At present there are no agents that inhibit lipoxygenase without
simultaneously inhibiting cyclooxygenase. In this investigation a
comparative study of the structural requirements of numerous acetylenic
analogues to preferentially inhibit either platelet cyclooxygenase or
lipoxygenase and to determine the effectiveness of these compounds to
inhibit human platelet aggregation was undertaken. From these studies
emerged a series of selective enzyme inhibitors that will permit the




Prostagiandins and Arachidonic Acid Metabolism
In 1930, Kurzrok and Lieb observed that strips of human uterus
relax or contracted when exposed to human seman (Kurzrok and Lieb,
1930). Subsequently, initial characteristics of prostaglandins were
discovered by Glodblatt (1933, 1935) and Von Euler (1934, 1936) who
independently reported smooth muscle contraction and vaso-depressor
activity in seminal fluid and reproductive glands. Von Euler identified
this active material as a lipid-soluble acid which he named "Prosta-
glandin." The structure of prostaglandins was elucidated by Bergstrom
and Samuelsson in 1963, which then paved the way for many biological
studies (Bergstrom, 1968).
Prostaglandins have a broad spectrum of effects. They have been
studied in many biological systems, most notably renal, cardiovascular
and respiratory. Prostaglandins (PGs) consist of 20 carbons having a
cyclopentane ring and two aliphatic side chains that may contain one,
two or three double bonds. PGs are formed by enzymatic oxygenation of
certain essential polyunsaturated fatty acids consisting of either
three, four or five double bonds. These precursor fatty acids are:
series one, containing three double bonds, 8,11,14-eicosatrienoic acid
(dihomo-Y-linolenic acid); series two, consisting of three double bonds,
5,8,11,14-eicosatetraenoic acid (arachidonic acid); and series three,
having five double bonds, 5,8,11,14,17-eicosapentaenoic acid. There is
little evidence that prostaglandins of the one or three series are
important in humans; however, significant amounts of series three are
present in fish and marine animals.
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Arachidonic acid, in man, is the most abundant precursor of prosta-
glandins. It is released from membrane phospholipids by the activation
of a lipase. Once released, it is rapidly metabolized to oxygenated
products by two distinct enzymatic mechanisms, cyclooxygenase and lipoxy-
genase, or reacetylated for insertion back into the phospholipid.
In the cyclooxygenase pathway, the free unesterified precursor acid
(arachidonic) is oxygenated and cyclized to form the cyclic endoperoxide
derivatives prostaglandin G (PGG2), a hydroperoxide, and prostaglandin H2
(PGH2), a hydroxy acid. These two chemically unstable compounds may be
metabolized by a isomerase or reductase to PGE?, PGF? , and PGD9. PGHO
is metabolized into two other compounds, thromboxane Ap and prostacyclin
(PGI2), which are unstable and highly biologically active. Thrombox
ane A2 (TxA2), produced by the enzyme thromboxane synthetase, later
breaks down nonenzymatically into the stable metabolite thromboxane B?
(TxB2; Hamberg et al^, 1975; Piper and Vane, 1969). Also, a 17-carbon
hydroxy acid (HHT) can be formed nonenzymatically from thromboxane
synthetase (McMillian e_t al_^, 1978; Anderson et ajL^, 1978). These two
metabolites, thromboxane B2 and HHT are produced exclusively in human
platelets. The other unstable compound, prostacyclin (PGIJ, is formed
by the enzyme, prostacyclin synthetase, and is later hydrolyzed nonenzy-
matically to a stable compound 6-keto-PGFn .
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Other metabolic products of arachidonic acid originate from the
lipoxygenase pathway. This enzyme was first identified in plants and
the discovery of the mammalian enzyme was initiated by Hamberg and
Samuelsson in 1974. In contrast to cyclooxygenase, which is widely
distributed, lipoxygenase has been found in lung, platelets and leuko
cytes. The compounds produced by the lipoxygenase enzyme are a family
of mono and dihydroxy fatty acids. Little is known about the pharmaco-
logical activity of these compounds, although 12-HETE (12-hydroxy
5,8,10,14-eicosatetraenoic acid), which is found in increasing amounts
in human platelets, is believed to be chemotactic for polymorphonuclear
leukocytes and alveolar macrophages (Sun et cfL_, 1977; Fig. 1).
It has been shown that the arachidonic acid is a precursor for a
family of compounds called leukotrienes. Included in this group is an
inflammatory mediator termed SRS-A (slow-reacting substance of anaphyl-
axis), which is a product of a separate lipoxygenase pathway not yet
studied in platelets (Jakschik et_ al_^, 1978).
Aspirin-Like Drugs
Aspirin irreversibly acetylates the enzyme (Roth et aj^, 1975)
inhibiting the cyclooxygenase but not the peroxidase activity; other
nonsteroid antiinflammatory drugs demonstrate the same inhibitory pat
tern, but reversibly. Among such drugs are meclofenamic acid, indometha-
cin, mefenamic acid, naproxen, phenylbutazone and ibuprofen (Flower,
1974). Eicosatetraynoic acid (ETYA) inhibits both cyclooxygenase and
lipoxygenase activity; related acetylenic fatty acids display differen
tial specificities (Wilhelm et al_^, 1981; Sun etaL., 1981; Chapter III,
Fig. 3). Other fatty acids, including oleic, linoleic, and linolenic
acid also inhibit PG synthesis (Pace-Asciak and Wolfe, 1968). Cyclooxy
genase inhibition by many fatty acids has both concentration and time
dependent components (Flower, 1974). Several endogenous cyclooxygenase
inhibitors have been reported but are not well-characterized (Saeed et
al., 1977; Terragno et al^, 1978; Fig. 2).
There are some experiments which suggest that endoperoxide synthe-
tase is coupled in some fashion to enzymes acting on its metabolites.
For example, little or no endoperoxide escapes the platelet enzyme






















































Fig. 2. Enzymes and inhibitors of prostagiandin biosynthesis,
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and HHT (Needleman et £L.» 1979). Only in the presence of a thromboxane
synthetase inhibitor, such as imidazole, are alternate products observed.
Platelets
A. Production
Platelets are derived for the megakaryocytes of bone marrow by a
process that leaves each platelet without a nucleus, with little endo-
plasmic reticulum or RNA of any type (Becker et aJL_, 1963). Platelets
are unable to respond to environmental influences via RNA transcription
and subsequent translation to form new proteins. Under normal condi
tions, platelets circulate in the blood for 10 days as smooth disc
shaped cells that are non-adherent to each other and to normal vascular
endothelium (Marcus e_t aj^, 1978). Platelets have unusual biological
properties which will cause them to adhere to collagen, fragments of
basement membrane and microfibrils afterward forming a haemostatic plug
(aggregation; Wright and Minot, 1917), through a process in which the
platelet undergoes a secretory phase during which substances found in the
granules in the platelets are secreted (release reaction; Grette, 1962).
This may occur when the endothelium lining in the blood vessel is broken
or when disruption of the vessel allows the blood to come into contact
with elements of the vessel wall on subendothelial tissue.
B. Aggregation
During the development of the haemostatic plug, two secreting types
of granules have been identified within the cytoplasm of platelets. The
majority, which are known as alpha granules, contain enzymes such as
cathepsin and acid hydrolases that are characteristically associated
with lysosomes ranging from 20-200 granules per platelet (White, J.C.,
1972). The second type of granule, called a dense body, not nearly as
numerous but ranging between 2-10 per platelet, contains the storage
sites for ADP, adenosine triphosphate (ATP), serotonin and calcium
through studies by David and White (1968). The serotonin storage is
similar to the catecholamine storage in the dense core granules of the
adrenal medulla. In vitro evidence indicates that serotonin can associ
ate with ATP and calcium or magnesium as micelles, whereas in vivo is
still uncertain.
The ADP stored in the dense bodies accounts for over 50% of the
total ADP in human platelets. This ADP is nonmetabolic, or storage pool
ADP, which is to be distinguished from the metabolic pool of ADP (Holmsen
et aj^, 1969). The ADP actively participates in the metabolism of the
blood platelet and provides energy for maintenance of the membrane
transport systems, and responses to stimuli as aggregation.
Holmsen and Day correlated the release reaction with the alpha
granules and dense bodies (Day and Holmsen, 1971). They have called the
selective process that releases the contents of the dense bodies,
Release I, and the process that releases the contents of the alpha
granules, Release II. Recent evidence confirming the separation of
these two processes has been the finding that aspirin can inhibit
Release I but not Release II, suggesting that these two processes may be
governed by different mechanisms (Holmsen e_t cfL_, 1975).
Thus, the events following vascular injury occur in the following
sequence: adhesion, release reaction, platelet aggregation, primary
haemostatic plug and arrest of bleeding.
C. Arachidonic acid response to aggregation
Arachidonic acid, PGG2 and PGH2 cause platelet aggregation and
release of dense body granules, including ADP (Hamberg ejt aj_^, 1975;
Vargafting and Zirinis, 1973). Thromboxane A2 was deduced to be an
aggregative agent more potent than either PGG9 or PGH, (Hamberg et al.,
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1975). Imidazole blocks thromboxane A2 synthesis but does not affect
arachidonic acid-induced aggregation or release in wash platelet suspen
sion (Needleman et &L_, 1977). Consequently, PGH2 is sufficient and
thromboxane A2 is not necessary to mediate arachidonic acid-induced
platelet aggregation. The conclusion has been challenged by Gorman ejt
a"l- (1977), who found that a synthetic thromboxane A2 analogue inhibited
the effects of PGH2 upon human platelets without increasing cAMP.
However, the selectivity of the analogue for competition with A2 against
the prostaglandin endoperoxides is not established.
The role of HETE and HHT in platelet aggregation and release is
unclear. Platelets incubated with exogenous arachidonic acid also
synthesize very small amounts of PGE2, PGF2a and PGD2. PGD2 is an
inhibitor of human platelet aggregation and release; also, PGD2 has been
postulated to act as a feedback inhibitor of arachidonic acid-induced
platelet aggregation and release (Oelz et al., 1977). PGE0 facilitates
platelet aggregation (Weiss et al^, 1976). Prostacyclin (PGI2) has been
shown to be a \/ery potent inhibitor of arachidonic acid-induced platelet
aggregation and release (Moncada ejt ajL_, 1976), but this molecule has
not been demonstrated to be synthesized by platelets. Finally, PGE, is
also a potent inhibitor of platelet aggregation and release in vitro
(Sinha and Colman, 1978). PGD2, PGI2 and PGE] probably exert their
inhibitory action by increasing platelet cAMP concentration (Tateson e_t























[ C]-Arachidonic acid (AA; sp. act., 55 mCi/mmol) was obtained
from New England Nuclear, Boston, MA. Prostaglandin (PG) standards were
supplied by Dr. John Pike of The Upjohn Company, Kalamazoo, MI. Thin
layer chromatography plates were from Brinkman Instruments, Westbury,
NY. Inophore A32187 was from Calbiochem, La Jolla, CA. Thrombin was
obtained from Drs. Craig Jackson and Phillip Majerus, Washington
University, St. Louis, MO. Acetylenic compounds were synthesized and
kindly suppled by Dr. Howard Sprecher, Department of Physiological
Chemistry, Ohio State University, Columbus, OH.
Methods
Preparation of Washed Platelets
It is important to take a medical history from the patient at the
time of testing and a complete list of all medication should be noted to
the aggregation results. Aspirin-like drugs have simultaneously shown
to inhibit prostaglandin release from human platelets and must absolutely
be avoided. It is also important that in preparation of platelets, be
sure to use well si 1 iconized glassware or plastic ware. Contact with
glass will cause aggregation of platelets.
Blood from a healthy donor was collected in 2.6 ml of 0.077 M EDTA
for every 35 ml of whole blood. The blood was then centrifuged for
10 minutes at 1000 rpm at room temperature. After spinning, the super
natant was removed with a plastic pi pet and transferred into a 15 ml
conical tube and plasma volume noted. The plasma was then centrifuged
6 minutes at 4000 rpm at room temperature. Following centrifugation,
12
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the supernatant was discarded and the platelets pellet was resuspended
in wash fluid to a volume of 2 ml less than original plasma volume. The
suspension was gently mixed and centrifuged 5 minutes at 2000 rpm at
room temperature. After centrifugation, the supernatant was discarded
and the pellet immediately resuspended with zero calcium Krebs solution
to a volume of 1/2 ml less than the original volume. The platelets were
then in the final form and were ready to use. The platelets are good up
to 3 to 4 hours and testing should be started within 30 minutes of
collection.
Solution for Preparation of Platelets Suspension
0.077 M EDTA (Ethylenediamine Tetraacetic Acid Trisodium salt)
12.9 gms in 500 ml of distilled water
Wash Fluid
90 parts 0.15 M NaCl
8 parts 0.15 M Tris-HCl
2 parts 0.077 M EDTA
0.15 M NaCl
8.7 gms in 1 liter distilled water





Note: Add above ingredients to approximately 1/2 the amount of distilled
water needed; then fill to 1 liter. Stir for approximately 1 hour.
Solution is stable indefinitely. Store at 4°C.
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Zero Calcium Krebs Solution
890 ml Distilled Water
100 ml Zero Calcium Krebs lOx Stock
10 ml Dextrose 100 Stock
2.1 gms Sodium Bicarbonate
Dextrose lOOx Stock (3.5 liters)
630 gms of dextrose powder was added to 2 liters of stirring
distilled water; then distilled water added to 3.5 liters.
Store at 4°C.
Platelet Aggregation Method
Aggregation was assessed photoelectrically in a temperature con
trolled, continually stirred siliconized system (Payton Dual Channel
Aggregometer) that was connected to a strip recording chart (Beckman R511
Recorder). Human washed platelets (WP), which were used in all experi
ments, are turbid and stirred continually in a glass cuvette. The
transmittance of light through the sample relative to the WP blank is
recorded. When the aggregating agent was added, the formation of in
creasingly large platelet aggregates is accompanied by a clearing in the
wash platelets and, therefore, light transmittance through the sample is
increased. The light received through the sample is converted into
electronic signals, amplified and recorded on chart paper.
In this series of experiments ETYA was used as the control, and the
acetylenic acid analogs were first incubated in 0.3 ml of wash platelets
at 37°C in the aggregometer for 3 minutes before the addition of the
aggregating agents.
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Aggregating Agents - Stock Solutions
Arachidonic Acid (AA) 100 yg/ml
Thrombin 90 m/U store at 20°C
Ionophore (A23187) 100 yg/ml
ETYA 100 yg/ml to 1 mg/ml
Acetylenic Acids Analogs 100 yg/ml to 1 mg/ml
All of the above agents were resuspended in 0.9% saline except A23187
which was resuspended in 50 mM P04 buffer. Thrombin and A23187 should
be kept on ice while the ETYA and acetylenic analogs should be wrapped
in foil and kept at room temperature while in use.
Preparation of Glassware and Stir Bars
Glassware, cuvettes and stir bars were siliconized with Prosil-28
si 1 iconizing solution.
Radiochemistry
The human washed platelets (WP) were prepared as described earlier.
Washed platelets (0.4 ml) were preincubated along with acetylenic acid
ranging from 0.8 yM to 25.0 yM for 5 minutes at 37°C using an immersible
magnetic stir bar. After preincubation, the mixture was incubated an
additional 20 minutes with 100 yl of [14C]-arachidonic acid (300,000 cpm)
Extraction
After incubating add 100 yl of 2 N formic acid to the incubation
mixture (spot check pH which should range between 3-3.5, mix well). The
extraction was done twice with equal or larger volume of ethyl acetate
and mixed well. After mixing completely the organic layers were then
combined. (If the layers do not separate, add a few crystals of NaCl,
mix and centrifuge 1000 rpm for 2 minutes).
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Thin Layer Chromatography
The extract was then totally dried under N2 and 50 pi of 2:1 chloro-
formrmethanol was added, rinsing the walls of the tubes well, followed
by the addition of 1 drop of cold prostaglandin (PG) standard. The
solution was then streaked in lanes on silica gel plates. Each sample
was rinsed with an additional 20 ml of 2:1 chloroform:methanol and
allowed to dry at room temperature.
System C
Solvent system C (CHCl3:Me0H:Acetic Acid:Distilled H2O; 90:80:1:0.8)
was made up fresh daily and allowed-to equilibrate for 1 hour. The
platelet was allowed to run from 1-1/2 to 2 hours.
Development of X-Ray
After chromatography, the plates were dried and positions of the PG
standards were determined by iodine staining. After identifying the
standards on plates, the plates were left to stand until the iodine
stains had dissolved. The thin layer chromatography plate was then
placed on Kodak X-Omat R X-ray film in a cassette at room temperature
for 48 hours.
Qualitative and Quantitative Analysis
After developing, the positions of the zones were compared to that
of the standards as visualized by iodine vapor, the appropriate lanes
were cut and were counted (qualitative) in scintillation fluor (4a20-
RPI Corp) in a Beckman LS-230 scintillation counter.
For the quantitative approach, the actual X-ray plate was scanned
by a Joyce-Lobe! Densitometer and the area under the curve formula was
used for each identifiable band that was detected to determine its
quantity.
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A complete dose-response curve was constructed. The term IC™
bu
designated the concentration of acetylenic compound required to cause a
50% reduction in response compared to the control. The IC5Q for cyclo-
oxygenase was calculated as the concentration of ETYA analogue needed to
cause a 50% reduction in the sum of the TxB2 and HHT zones from the thin
layer plates. The IC5Q for lipoxygenase was calculated from the HETE
peak. Each experiment was repeated 3 to 4 times and mean values were
determined. The standard errors were 10-15% of the mean. In each
aggregation or radiochemistry experiment ETYA was run as a control
antagonist.
Radiochemistry Solutions
Indomethacin 10 mg/ml: To 100 mg of powder add 10 ml of 0.1 M
Tris buffer pH 8.2 and 4-6 drops of 1 N NaOH. Mix for 10 min
utes before adding more NaOH. Store at 40°C, stable for
several days.
1 M Tris Buffer
1 M Tris base 40.3 ml
4 N HC1 3.2 ml
pH 8.2
Add sufficient distilled water to make 400 ml
1 M Tris Base
Tris base (Sigma) 60.5 g











Fig. 1. The above data represents the effectiveness of the Joyce
Lobe! Densitometer. This instrument was used to scan actual
X-ray plates to obtain the area under the curve.
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Acetylenic Acids
1. 18:4 A5 w4 5,8,11,14 octadecatetraynoic acid
2. 19:4 A5 co5 5,8,11,14 nonadecatetraynoic acid
3. 18:3 A5 w7 5,8,11 octadecatriynoic acid
4. 21:4 A5 o>7 5,8,11,14 heneicosatetraynoic acid
5. 20:3 A5 o>9 5,8,11 eicosatriynoic acid
6. 19:3 A5 o>8 5,8,11 nonadecatriynoic acid
7. 19:4 A6 o)4 6,9,12,15 nonadecatetraynoic acid
8. 20:4 A6 co5 6,9,12,15 eicosatetraynoic acid
9. 18:3 A6 o)6 6,9,12 octadecatriynoic acid
10. 22:4 A4 o)7 6,9,12,15 docosatetraynoic acid
11. 21:3 A6 o)9 6,9,12 heneicosatriynoic acid
12. 18:4 A6 oi3 6,9,12,15 octadecatetraynoic acid
13. 20:3 A6 o)8 6,9,12 eicosatetriynoic acid
14. 20:4 A7 oj4 7,10,13,16 eicosatetraynoic acid
15. 22:4 A7 o)6 7,10,13,16 eicosatetraynoic acid
16. 20:3 A7 o)7 7,10,13 eicosatriynoic acid
17. 21:3 A7 o)8 7,10,13 heneicosatriynoic acid
18. 18:3 A8 o)4 8,11,14 octadecatriynoic acid
19. 21:4 A8 oi4 8,11,14,17 heneicosatetraynoic acid
20. 19:3 A8 o)5 8,11,14 nonadecatriynoic acid
21. 20:3 A8 o)6 8,11,14 eicosatriynoic acid
22. 20:2 A8 w9 8,11 eicosadiynoic acid
23. 21:3 A8 o)7 8,11,14 heneicosatriynoic acid
24. 20:4 A8 oi3 8,11,14,17 eicosatetraynoic acid
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25. 22:3 A 8 oj8 8,11,14 docosatriynoic acid
26. 17:3 A 8 to3 8,11,14 heptadecatriynoic acid
27. 22:3 AlO to6 10,13,16 docosatriynoic acid
28. 20:2 AlO o)7 10,13 eicosadiynoic acid
29. 19:4 A 4 oj6 4,7,10,13 nonadecatetraynoic acid
30. 20:4 A 4 w7 4,7,10,13 eicosatetraynoic acid
31. 21:4 A 4 oj8 4,7,10,13 heneicosatetraynoic acid
32. 16:3 A 4 oj6 4,7,10 hexadecatriynoic acid
20:4 A 5 o)6 5,8,11,14 eicosatetraynoic acid (ETYA)





When identifying long chain fatty acid structures, it is customary to
name the structure either by its omega (w) or delta (A). Omega desig
nates the position of the last double bond counted from the terminal (<o)
carbon on the fatty acid. Delta designates the position of the first
double bond counted from the carboxyl end of the fatty acid. Thus, 20:4
(u5, A6) is 5,8,11,14-eicosatetraenoic acid (AA).
The following abbreviations are sometimes used when describing the
nature and geometry of carbon-carbon bonds in fatty acids:
C = cis -C=C-(ethylenic double bonds)
t = trans -C=C-(acetylenic triple bonds)
CHAPTER IV
RESULTS
T_he_ Effect of Acetylenic Acids on Platelet Arachidonate Metabolism
As a primary control of this metabolic study, 5,8,11,14-eicosatet-
raynoic acid (ETYA) was used. This particular acetylenic fatty acid
will simultaneously inhibit both the platelet lipoxygenase and cyclo-
oxygenase activity in a concentration dependent fashion with an ICrn of
50
1.7 yM (Fig. 1). The autoradiograph data from the radioctiemical experi
ment are presented in Fig. 2. The control (far right lane) illustrates
the separation of the metabolites following the incubation of intact
washed human platelets with [ C]-arachidonic acid. The primary cyclo-
oxygenase products were thromboxane B2 (TxB2) and a 17-carbon hydroxy
acid (HHT) and the primary lipoxygenase product was 12-hydroxy-5,8,10,14-
eicosatetraenoic acid (HETE). Also, there were trace amounts of other
metabolites that were visualized (i.e., PGE, PGD, PGF2 ).
After careful study of the acetylenic acids tested, they were
grouped in order of selectivity (i.e., inhibitors of cyclooxygenase,
lipoxygenase, cyclooxygenase and lipoxygenase, and neither; Table 2).
Preincubation of washed platelets with the acetylenic acids that simul
taneously inhibited both enzymes (22:3 A10 w6) results showed the dis
appearance of TxB2 and HHT with a consistant recovery of the lipoxygenase
product, HETE, at concentrations up to 30 yM. Quantitation of the
individual zones by scraping from the thin layer plate and counting
demonstrated, in fact, that the cyclooxygenase was inhibited and that
more of the arachidonic acid is shuttled into the lipoxygenase product,
HETE (Fig. 3A,B). Alternatively, a number of acetylenic analogues proved
to be selective lipoxygenase inhibitors. The autoradiogram presented in
22
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Fig. 4 demonstrates that 21:4 (A5, u>7) abolished the HETE band without
altering the cyclooxygenase products. In fact, careful quantisation
shows that more arachidonic acid is shuttled into the TxB2 and HHT bands
with enhanced lipoxygenase inhibition by 21:4 (A5, (j>7) (Fig. 5A,B)
(20:4 A4, a>7).
With the validation that the acetylenic acid analogue possessed a
high degree of selectivity for inhibition of the metabolic enzymes of
cyclooxygenase and lipoxygenase, the next step was to evalute the effects
of the compounds on the aggregation of platelets.
The data, in respect to platelet aggregation, rather strikingly
indicated a biomodal distribution of acetylenic acids based on their
rank order of potency to inhibit platelet aggregation (Table 1). The
acetylenic acid analogues that either selectively inhibited cyclooxygen
ase alone or inhibited both the cyclooxygenase and the lipoxygenase at
concentrations of <2.5 yM of arachidonate induced aggregation of washed
human platelet suspensions (Table 1). In contrast, the acetylenic acid
analogues that were potent lipoxygenase inhibitors, or that inhibited
neither the cyclooxygenase nor the lipoxygenase, were much less potent
in suppressing aggregation requiring <5 pM to produce a 50% inhibition.
There was no detectable difference in potency in suppressing arachi
donate induced platelet aggregation between the inactive acetylenic
acids (i.e., inhibited neither or both enzyme) and those that were
potent inhibitors of lipoxygenase alone. A comparison of the effective
ness as enzyme and aggregation inhibitors of all the acetylenic acids
tested are listed in Table 2. The fatty acid analogues are grouped
according to their enzyme specificity. Clearly, there is a direct
correlation between the potency of the analogues to inhibit cyclooxygen
ase and to suppress arachidonate induced platelet aggregation.
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Table 1. Comparative potency of acetylenic acid analogues as inhibitors





















Table 2. The rank order potency of acetylenic acid analogues as inhibi
tors of arachidonic acid metabolism and aggregation in washed
human platelets. The enzymatic IC5Q is the concentration of
acetylenic acid needed to cause a 50% reduction in the sum of
TxB2 and HHT for cyclooxygenase inhibition, or 50% fall in
HETE levels of lipoxygenase activity.
ACETYLENIC
ACID





















































20:2 7 10 6.7



























































ACID to A --JC50— IC.Q
5)0 ymole/1 t>0
IV. INHIBITS NEITHER CYCLOOXYGENASE NOR LIPOXYGENASE
20:2 9 8 0 6.3
21:3 8 7 0 4.8
19:3 8 5 0 5.4
18:3 7 5 0 4.8
16:3 6 4 0 21.0
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Table 4. Comparison of 20-carbon acetylenics on platelet arachidonate






































Fig. 1. Concentration dependent inhibition of arachidonic acid














Fig. 2. Autoradiograph of the effects of the acetylenic fatty acids
22:3 (to6) and 20:2 (w7) on platelet arachidonate metabolism.
The diynoic fatty acid 20:2 (oj7) inhibited only the TxBp and
HHT and enhanced the HETE peak control representing 20:4 (co6)
(AA). Authentic standards were applied on both sides of the
thin layer chromatogram and were visualized by iodine staining.
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Fig. 3A. Concentration dependent inhibitors of platelet cyclooxygenase
and simultaneous enhancement of the lipoxygenase by 18:4 (o)4).
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Fig. 3B. Concentration dependent inhibitors of platelet cyclooxygenase
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21:4 (u>7)
Fig. 4. Autoradiograph of the effectiveness of the 21:4 (a>7) acetylenic
analogue as a lipoxygenase inhibitor.
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Fig. 5A. Concentration dependent inhibition of platelet lipoxygenase
by the 21:4 (oo7) analogue.
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Fig. 5B. Concentration dependent inhibition of platelet lipoxygenase
by the 20:4 (oj7) analogue.
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Fig. 6. Concentration dependent inhibition of platelet 22:4 (to7)
inhibition of both.
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Fig. 7. Concentration dependent inhibition of platelet 16:3 (w6)
inhibition of neither lipoxygenase nor cyclooxygenase.
CHAPTER V
DISCUSSION AND SUMMARY
The data clearly differ from that of Dutilh et a]_^ (1978, 1981) who
demonstrated that ETYA was a more potent inhibitor of lipoxygenase than
cyclooxygenase and that the former enzyme influences platelet aggrega
tion. In this particular system ETYA had a equipotential as a lipoxygen
ase and as a cyclooxygenase inhibitor. Similary, Hammarstrom et al.
(1977) and Sun e_t aj_^ (1981) have found no apparent selectivity of ETYA
in suppressing platelet arachidonic metabolism. Our data demonstrating
the direct relationship between cyclooxygenase and aggregation seem to
correlate for a large number of analogues.
The number of analogues studied permits a partial analysis of
structure activity relationships. If acetylenic fatty acids that possess
their initial triple bond at the 5 position (i.e., A5) are compared,
some conclusions can be drawn (Table 3). The triynoic analogues (18-20
carbons) that possess three triple bonds and lack A14 are ineffective as
cyclooxygenase inhibitors and are impotent as inhibitors of platelet
aggregation. Goetz e_t aJL_ (1976) have previously studied some 20 carbon
triynoic acid analogues and observed that the rank order of potency for
the inhibition of bovine seminal vesicle cyclooxygenase and the inhibi
tion of platelet aggregation was as follows: 20:3 (u6)>20:3 (ui7)>20:3
(w9). We found that both 20:3 (w8) and 20:3 (w6) were potent cyclooxy
genase inhibitors and potent inhibitors of platelet aggregation, while
20:3 (o>9) inhibited platelet lipoxygenase only and was a weak antithrom-
botic agent (Table 2). Comparison of the triynoic acetylenic derivatives
with triple bonds at positions 8,11,14 (i.e., A8) clearly demonstrates
that unsaturation at A14 is critical for inhibition of cyclooxygenase
38
39
activity, whereas the lack of the triple bond at A5 is not essential to
suppress TxA2 biosynthesis (Table 3). This relationship seems fairly
independent of chain length, i.e., from 17-20 carbon acetylenics; how
ever, when the chain length was extended to 20 carbons, the analogue no
longer inhibited the cyclooxygenase but was preferentially effective
against the 12-lipoxygenase and, therefore, a poor antithrombotic agent.
The tetraynoic analogues that possess triple bonds at the 5,8,11,14
positions demonstrate the impact of the length of the co-carbon chain.
Thus, with 18-20 carbons they are potent inhibitors of cyclooxygenase
and platelet aggregation (Table 3). At 20 carbons the to5 acetylenic
fatty acid inhibits both cyclooxygenase, while further extension of the
w-chain to 21 carbons results in a compound which inhibits only the
lipoxygenase. Variation of the position of the triple bonds also pro
foundly influences the inhibitory effects of these analogues. With the
chain length fixed at 20 carbons and comparing only tetraynoic acid
compounds, it appears that the co3, w4, and to5 compounds inhibit cyclooxy
genase only and are inhibitors of aggregation (Table 4). The w6 compound
(ETYA) inhibits both, but the to7 inhibits lipoxygenase only.
The apparent lack of participation of the 12-lipoxygenase in plate
let aggregation leaves the function of this enzyme unresolved in this
tissue. An exciting possibility was recently demonstrated by Borgeat at
the 1981 Winter Prostaglandin Meeting (April, 1981). His work indicated
that leukocytes metabolized arachidonic acid to 5-HETE. However, when
he mixed leukocytes and platelets, 5,12-diHETE was formed, suggesting
the transfer of the 5-HETE to platelets where the 12-lipoxygenase cat
alyzed the formation of 5,12-diHETE. Thus, two cell types were required
to participate in the synthesis of a potent biological compound. Such
cell-cell communication and interaction would have profound implications.
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In summary, the availability of agents with such a wide spectrum of
activity provides a family of tools that will permit discrimination of
metabolic pathways. What remains to be determined is the utility of
these analogues in other cell types (see Appendix).
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Utilizing a cell-free enzyme system for the synthesis of the dif
ferent leukotrienes we studied various factors influencing leuko-
triene synthesis. We found that calcium stimulates the first step
in the pathway (arachidonic acid -»■ 5 hydroperoxy arachidonate) and
that glutathione is essential for the formation of slow reacting
substance (SRS, leukotriene C and D). An investigation of the
unsaturation requirements of polyenoic fatty acids as substrates
showed that double bonds located at positions 5,8,11 were important.
Thus such fatty acids as 20:4 (5,8,11,14), 20:5 (5,8,11,14,17) 20:3
(5,8,11,), 19:4 (5,8,11,14) and 18:4 (5,8,11,14) were readily
converted to compounds that comigrated with 5-HETE and 5,12-DiHETE
(leukotriene B) and to biologically active SRS. Chain length did
not have an influence on the formation of these hydroxyacids.
Fatty acids with the initial unsaturation at A » A ., A or A
were poor substrates for the leukotriene enzyme system. The double
bond requirement at positions 5,8,11 and the stimulation by calcium
distinguishes this lipoxygenase enzyme system from the lipoxygenase
in platelets. Studying the effect of acetylenic acid analogs on
leukotriene formation, we found that 8,11,14-icosatriynoic acid
seems to block the synthesis of leukotriene A, as well as SRS, but
not the initial lipoxygenase which converts arochidonic acid into
5-HPETE.
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The availability of a simple cell free enzymatic generating system
for leukotrienes allows the study of the formation of these compounds
in detail. With such a system substrate and cofactors can be readily
controlled and one need not be concerned about uptake into tissue or
cells. We obtained a cell-free leukotriene enzyme system by homoge
nizing rat basophilic leukemia (RBL-1) cells under gentle conditions
in the presence of EDTA and indomethacin (Steinhoff et a!., 1980,
and Jakschik et al. 1980a).
Stimulation of leukotriene formation by calcium. The formation of
5,12-DiHETE (leukotriene B) was studied by incubating the 10,000 xg
supernatant with C-arachidonic acid. The products formed v/ere
separated by thin layer chromatography and quantitated by scraping
the radioactive bands and liquid scintillation spectrometry. When
the 10,000 xg supernatant was incubated with C-arachidonate
alone, only insignificant amounts of lipoxygenase products v/ere
synthesized. However, the addition of calcium markedly stimulated
the formation of hydroxyacids (Jakschik, et al, 1980). Two major
products were observed 5-HETE and 5,12-DiHETE. Upon addition of
1 mM calcium 20-40% of the added arachidonic acid v/as converted to
5,12-DiHETE and 10-25% to 5-HETE. This enhancement by calcium was
dose dependent. A similar enhancement by calcium v/as observed when
SRS synthesis was studied (B.A. Jakschik and L.H. Lee, 1980).
The stimulation of this pathway by calcium was suggested earlier when
we observed enhanced formation of leukotrienes when RBL-1 cells
were incubated with arachidonic acid in the presence of the calcium
ionophore A23187 (Jakschik et al. 1977 and 1978). Similar results
were reported by Borgeat and Samuelsson (1979) for polymorphonuclear
leukocytes. Calcium probably acts at the first step (arachidonic
acid --> 5-hydroperoxyarachidonate) since in the absence of exogenous
calcium neither 5,12-DiHETE nor 5-HETE were formed in significant
amounts. The calcium dependence of this pathway in basophils is
of great interest. It suggests a close relationship between leuko
triene formation and the release reaction of these cells which is
well known to be calcium dependent.
Modulation of leukotriene formation
Effect of glutathibne on leukotriene formation. The cell-free
enzyme system was also utilized to study SRS formation. The syn
thesis of SRS was monitored on the isolated, perfused guinea pig
ileum (Jakschik et al., 1978). It is very likely that a mixture of
leukotriene C and D (Parker et al, 1979; Orning et al, 1980) is
formed by the 10,000 xg supernatant of RBL-1 cells. These studies
of SRS formation with the cell-free enzyme system showed very
clearly that glutathione is essential for the synthesis of these
leukotrienes. Addition of cysteine to the incubation mixture in
stead of glutathione did not produce SRS activity. The SRS activity
generated by this cell-free enzyme system was readily blocked by
the specific SRS receptor antagonist FPL55712 (Augstein et al, 1973).
The addition of glutathione to the incubation mixture did not only
produce SRS but also reduced the formation of 5,12-DiHETE (Jakschik
and Lee, 1980). This observation suggests the preferential forma
tion of SRS over 5,12-DiHETE when relatively low concentrations of
substrate are available. .,?
-LJ^ for leukotriene enzymes.
Utilizing a variety of fatty acids, differing in chain length, de
gree and position of unsaturation, we investigated the substrate
specificity for the enzymatic production of biologically active
SRS and of the other luekotrienes (Jakschik et al, 1980b). The
various fatty acids, except arachidonic acid and dihomo-y-linolenic
were prepared by total organic synthesis (Sprecher, 1971). The
primary structural requirement observed for the conversion by this
lipoxygenase enzyme system was an unsaturation in a polyenoic fatty
acid at 5,8,11. Such fatty acids as 20:4 (5,8,11,14) 20:5 (5,8,11,
14,17), 20:3 (5,8,11), 19:4 (5,8,11,14) and 18:4 (5,8,11,14) were
excellent substrates for these enzymes. These fatty acids were read
ily converted to compounds that comigrated with 5-HETE and 5,12-
DiHETE and to biologically active SRS. Chain length appeared to be
less of an influence on the formation of these hydroxyacids. Fatty
acids with the initial unsaturation at A , A , A7 or A8 were a
poor substrate for the leukotriene enzyme system.
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The finding that 20:5 (5,8,11,14,17) and 20:3 (5,8,11) are readily
converted and form a potent SRS has pertinent biological implica
tions. 20:3 (5,8,11) accumulates in essential fatty acid deficiency
and is not converted by the cyclooxygenase (Ziboh et al, 1972).
20:5 (5,8,11,14,17) is a poor substrate for platelet.cyclooxygenase
and in fact is a good antagonist (Needleman et al, 1979 and
Whitaker et al, 1979). It is thought that this mechanism may
explain the supressed platelet aggregation observed in Greenland
Eskimos who possess a high 20:5 to 20:4 ratio in their tissue lipids
because of their cold water fish diets (Dyerberg et al, 1978).
These discoveries have stimulated an interest in dietary manipula
tion to increase 20:5 tissue levels. The observation that 20:5 is
readily converted into the potent bronchoconstrictor, SRS, suggests
a re-evaluation of such a dietary manipulation of fatty acid levels,
especially in asthmatics. The formation of leukotrienes from 20:5
(5,8,11,14,17) and 20:3 (5,8,11) has also recently been reported by
Samuelsson and Hammarstrom (1980).
The requirement of a double bond in the 5>8,11 position for leuko-
triene formation clearly differentiates this enzyme system from
the platelet lipoxygenase which does not have such a double bond
requirment for substrate. The platelet lipoxygenase is also not
stimulated by calcium (Jakschik et al, 1980a).
Inhibition by A acetyienic acids. In recent investigations with
the cell-free enzyme system we tested the effect of different
o
acetylenic analogs of arachidonic acid. Studies with A acetylenic
acids indicate that these compounds might block different steps in
the leukotriene pathway. As can be seen from Figure 1 and 3
8,11,14-icosatriynoic acid somewhat inhibited 5,12-DiHETE forma
tion and had no effect on 5-HETE synthesis. However the inhibition
of SRS was significantly greater than 5,12-DillETE. At an
acetylenic acid concentration of 3 yg/ml 5,12,-DiHETE synthesis
is not significantly different from control, but SRS formation
is inhibited by 50% (Fig. 3). From this data we conclude that
8,11,14-icosatriynoic :acid inhibits the pathway at tv/o points:
Modulation of leukotriene formation
it partially blocks leukotriene A formation and also acts at a
later step inhibiting SRS (leukotriene C and D) synthesis (see
Fig. 4). This acetylenic acid, therefore, inhibits a certain
specificity for different steps in the leukotriene pathway.
Other acetylenic acid analogs tested so far block the lipoxygenase
which converts arachidonic acid to hydroperoxy-arachidonate.
o
Work with A acetylenic acid with different carbon chain length
indicates that as the carbon number is increased the tendency to
block at the first step (arachidonate ->• 5HPETE) increases (Sams
et al, 1980). The results suggest that by manipulating carbon
chain length and position of acetylenic bonds it might be possible
to obtain fatty acid analogs which will inhibit the formation of
one leukotriene and not another.
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£igurej_: Effect of 5,8,11-icosatriynoic acid (18:3 (8,11,14)) on
5,12-DiHETE formation. 0.5 ml of 10,000 xg supernatant of RBL-1
cell homogenate was preincubated for 15 min, 4°C, with Ca++, 1.5
niM, and 18:3 (8,11,14), 20 pg/ml. Then 14C-arachidonic acid (AA),
200,000 cpm, v/as added and the mixture incubated for 15 min at
37°C. In the control 8,11,14-icosatriynoic acid v/as omitted. The
protein was precipitated with 3 volumes of acetone and the super
natant acidified (pH 3.4) and extracted twice with 2 ml of chloro
form. Thin layer chrornatography was performed in the organic
phase of ethyl acetate: 2,2,4-trimethyl pentane:acetic acidrwater
(110:50:20:100). The bands were visualized by fluorography and
quantitated by scraping and liquid scintillation counting.









i- Effect of the 8,11,14-icosatriynoic acid (18:3 (8,11,
14)) on SRS formation. 10,000 xg supernatant of RBL-1 cell homog-
enates was preincubated at 4°C for 15 min with Ca++, 1.5 mM and
18:3 (8,11,14) as indicated. Then arachidonic acid, 1 yg/ml, and
GSH, 1 mM, were added and the mixture incubated for 20 min at 37°C.
The acetylenic acid was omitted in the control. The incubation
mixture (0.2 ml) was applied directly to the superfused guinea pig
ileurn. The size of the contractions were compared utilizing the
area under the curve.





- Dose-dependent effect of 8,11,14-icosatriynoic acid
(18:3 (8,11, 14)) on leukotriene synthesis. For experimental
details see legend of figures 1 and 2. The data are presented as
mean ± SEM (n=8, 5-HETE and 5,12-DiHETE; n=5 SRS).







.: Schematic of the site of action of 8,11,14-icosatriynoic
acid (18:3 (8,11,14)).
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Utilizing a variety of fatty acids, differing in chain length,
degree and position of unsaturation, we investigated the substrate
specificity for the enzymatic production of biologically active slow
reacting substances (SRS) and of the other leukotrienes. A cell-
free enzyme system obtained from RBL-1 cells was used in this study.
The primary structural requirement observed,for the conversion by
this lipoxygenase enzyme system was a a°'b>" unsaturation in a
polyenoic fatty acid. Such fatty acids as 20:4 (5,8,11,14), 20:5
(5,8,11,14,17), 20:3 (5.8,11), 19:4 (5,8,11.14) and 18:4 (5,8,11.14)
were readily converted to compounds that comigrated with 5-HETE and
5,12-DiHETE and to biologically active SRS. Chain length did not
haye an influence on the formation of these hydroxyacids. Fatty
acids with the initial unsaturation at A , A , A or A were a poor
substrate for the leukotriene enzyme system. Therefore, this lipoxy
genase pathway in leukocytes is quite different from the lipoxygenase
in platelets which does not exhibit this specificity.
Introduction
Me have reported earlier that rat basophilic leukemia (RBL-1)
cells produce the potent bronchoconstrictor SRS when stimulated with
the calcium ionophore A23187 (1) and that labeled arachidonic acid
(20:4, 5,8,11.14) is incorporated into slow reacting substance (SRS)
(2). SRS from guinea pig lung (3), a murine mastocytoma (4) and
,RBL-1 cells (5,6) has been shown to have a UV absorption spectrum
characteristic of conjugated trienes with a maximum at 280 ran. It
has therefore been proposed that SRS is formed by the same pathway
as other conjugated triene hydroxy acids synthesized by leukocytes
(4). The reaction sequence involves an initial lipoxygenase conver
sion of arachidonic acid to the 5 position mono-hydroperoxy acid
which is converted to 5-hydroxyicotetraenoic acid (5-HETE) or to a
*The work was presented in part at the Prostaglandin Meeting,
Snowbird, Utah, April 1980.




S-transferase incorporates glutathione into
'HP
prostaglandins and thromboxanes (10). However, no apparent
thP ««fJ?Mif?tty/ 1]>- In thls investigation we evaluated
i»nJh 2 ty °I a v?nety of fatt^ acids' differing in chain
length, degree and position of unsaturation, as substrates for the
RBL-1 leukotnene enzymes, as well as the extent of SRS receptor
glneranted°SRSs reSP°n$e act1vation of the variotJS enzymatically
Methods
Th CCi]S Were grown and harvested as described previously
1 2* Fnrfl6 n6}ls w^.washed with 50 mM phosphate buffer, pH 7.0,
S fl ' "i ' ige1fl" and 4 pM ^^ethacin, resuspended at
5 x 10 cells/ml and homogenized as described (13). The homogenate
was centrifuged at 10,000 x g and the supernatant used for the
a™ non the,stud> ?f hydroxy acid formation, [14C] fatty acids
(150,000 cpm) were incubated with 0.5 ml of the 10,000 x g superna
tant in the presence of 2 mM calcium chloride for 30 min The
reaction was stopped by precipitating the proteins with acetone.
fnL^l 1 ■ ?"Pernatan* w« adjusted to 3.2 and extraction per
formed twice with two volumes of chloroform. Thin layer chromatoq-
raphy was performed on silica gel plates in solvent system A9? thi
organic phase of ethyl acetate:2,2,4-trimethyl pentaneracetic
acid.-water (110:50:20:100) (14). Standards were visualized by
?^"f»H ??; .Radioactive Peaks were located by fluorography
(15) and quantitated by scraping and liquid scintillation counting.
™h it «/a?\Sy"!l!e?J!z™nby incubat1n9 the various fatty acids (5
?«?r]LV9Jr!H 1 WMth I°*°°0 ? 9 supernatant in the presence of 2 mM
calcium and 1 mM reduced glutathione for 15 min at 37°. SRS forma-
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tion was monitored on the isolated, superfused guinea pig ileum
The various fatty acids, except arachidonic acid and dihomo-y-
linolenic.were prepared by total organic synthesis (13-25 Ci/mol)
(16). [ C]-Arachidonic acid (55 Ci/mol) was obtained from New
England Nuclear (Boston, MA), [ \]-dihomo-Y-linolenic acid (55
Ci/mol) from Amersham (Arlington Heights, IL), arachidonic acid and
dihomo-y-linolenic acid from Nu Check Prep (Elyson, IL) and reduced
glutathione from Sigma (St. Louis, MO). 5-HETE was kindly supplied
by R.C. Kelly of the Upjohn Co. (Kalatnazoo, MI), icosatetraynoic
acid by Roche Laboratory and indomethacin by Merck, Sharp and Dohme
(West Point, PA).
Results
The formation of mono- and,piHETE from the various fatty acids
was investigated by incubating C-labeled fatty acids with the
10,000 x g supernatant fraction of indomethacin-treated RBL-1
cells in the presence of calcium. An illustrative autoradiograph of
a thin layer chromatographic separation is presented in Figure 1.
The primary detectable products produced from arachidonic acid were
5-HETE and 5,12-DiHETE. The structure of these products was pre
viously confirmed by their high performance liquid chromatography
separation profile and gas chromatographic - mass spectrometric
analysis (8). The migration of standards of these hydroxy fatty
acids are indicated in the center of the plate. The fatty acids
which possessed a 5, 8, 11 unsaturation were all readily converted
to products that comigrate with 5-HETE and 5,12-DiHETE regardless of
the degree of unsaturation. Thus, the 20:3 (5,8,11), 20:4 (5,8,11,-
14), and 20:5 (5,8,11,14,17) fatty acids all were excellent sub
strates for these enzymes. Chain length appeared to be less of an
influence than the necessity for double bonds at 5, 8, ll5as evi
denced by the striking differences in conversion of the A versus
the A -19 carbon tetraenoates (Fig. 1 and Table I). Fatty acids
with a AH unsaturation, such as 19:4 (4,7,10,13) and 19:5 (4,7,10,13,
16), were converted, though poorly, to a hydroxy acid which comi-
grated with 5-HETE and is presumably 4-HETE. However, conversion to
DjHETE was negligible. Fatty acids with their first double bond at
A , A , or A were hydroxylated to compounds which migrated further
than the 5-HETE standard.
The formation of SRS activity was monitored on superfused
guinea pig ileum assay strips. An aliquot of the reaction mixture
following incubation of the various fatty acids in the presence of
the enzyme, calcium and glutathione, was injected over a bank of
tissues. A profound contractile response was produced by the incu
bations containing the 20:3 (5,8,11), 20:4 (5,8,11,14), and 20:5
(5,8,11,14,17) fatty acids (Fig. 2). All of these fatty acids have
a double bond at 5, 8, 11. The response generated when arachidonate
was used as the substrate remained similar throughout the course of
the experiment. No contractile response was produced in the absence















£S>r ?ndnnnUt°9ram °f th1n }Per ch™atograms of fatty acid
and chromatography performed as indicated in Methods
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SRS-ACTIVITY: FATTY ACID* + ENZYME GENERATING SYSTEM
Guinea Pig Ileum
5pg/ml
Figure 2: SRS formation by various fatty acids. 10,000 x g super
natant of RBL-1 homogenates was incubated with the fatty acid indi
cated in the presence of 2 mM calcium and 1 mM glutathione for
15 min, 37°C. An aliquot of the incubation mixture was applied to
the superfused guinea pig ileum. FPL 55712 was applied to the
tissue in a 0.2 yg/ml concentration.
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TABLE I



















































































































*The various [ C]fatty acids were incubated with the 10,000 x g
supernatant of RBL-1 cell homogenates as described in the legend of
Figure 1. After chromatography, the radioactive bands were scraped
and quantitated by liquid scintillation counting. The data are
stated as mean ± SEM, n=6.
**The bioactivity was evaluated on the isolated perfused guinea pig
ileum as indicated in the legend of Figure 2. The relative SRS
activity generated from the different fatty acids was assessed by
comparing the contractile response produced to that of SRS synthe
sized from arachidonic acid. n=4-10.
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of GSH. The SRS receptor antagonist FPL 55712 efficiently abolished
the contractile response of the fatty acid incubations (Fig. 2).
The guinea pig ileum assay does not lend itself to accurate
quantitative comparison. Relative potency was assessed either by
trying to match the contractile response of the fatty acid under
study with the response produced by arachidonate or by comparing
jqual concentrations of the various fatty acids. An extensive
comparison of the various fatty acids is shown in Table 1. The
compounds appeared to subdivide into two groups based on the inten
sity of the biological response and the relative conversion to
DiHETE. The long chain (18-22 carbons) polyenoic fatty acids were
all enzymatically converted to active SRS-like compounds with the
possible exception of 21:4 (6,9,12,15). This latter fatty acid is
enzymatically converted by platelets or blood vessels into its
appropriate endoperoxide, thromboxane, and prostacyclin all of which
proved to be biologically inactive (10). The most striking result
was the parallelism between DiHETE and HETE formation and detectable
SRS activity and the obvious preference for a double bond at posi
tions 5, 8, 11 of the fatty acid. When the initial unsaturation was
in position 4, 6, 7, or 8 very much less hydroxy fatty acid was
formed (Table 1). The low SRS activity obtained from incubations of
these latter fatty acids could reflect the low conversion rate
and/or low biological activity. The latter issue will require
careful isolation of the leukotriene like compound for quantitation.
The SRS-like activity of all the fatty acids was abolished by the
absence of GSH, or by the receptor blocker FPL 55712. There was no
direct relationship between the suitability of the various fatty
acids as lipoxygenase substrates with the RBL-1 enzyme source
(leukotriene pathway) versus that from platelets (11).
Discussion
The primary structural requirement for conversion by the enzyme
of the leukotriene pathway appears to be the presence of 5, 8 11
unsaturation in a polyenoic fatty acid. There was a direct paral
lelism between the capacity of the enzyme system (in the absence of
GSH) to form the mono-and dihydroxy fatty acids and SRS (in the
presence of glutathione).
The finding that 20:5 (5,8,11,14,17) and 20:3 (5,8,11) are
readily converted and form a potent SRS has pertinent biological
implications. We previously demonstrated that 20:5 is a poor sub
strate for platelet cyclooxygenase even though this fatty acid is
readily incorporated and released from platelet phospholipids (17).
However, 20:5 is an effective antagonist of arachidonate metabolism
by platelet cyclooxygenase (17,18). Thus, 20:5 inhibits platelet
thromboxane A? formation which presumably interferes with platelet
aggregation. This latter mechanism may explain the suppressed
platelet aggregation observed in Greenland Eskimos that possess a
high 20:5 to arachidonate ratio in their tissue lipids because of
their cold water fish diet (19). These discoveries have stimulated
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an interest in dietary manipulation to increase tissue 20:5 levels.
The finding that 20:5 can readily be converted into the potent
bronchial constrictor forces a re-evaluation of the implications of
dietary manipulation of fatty acid levels. Indeed it seems worth
while to determine if the Greenland Eskimos have a predisposition to
bronchial constriction. It is conceivable that they may have en
hanced SRS formation with a fatty acid like 20:5 since none of the
substrate is diverted to prostaglandin or thromboxane synthesis. A
similar situation exists with 20:3 (5,8,11). This fatty acid accum
ulates in essential fatty acid deficiency and is not converted by
cyclooxygenase (20). Thus, fatty acids that were thought to be
biologically inactive may well be precursors of SRS.
Morris" £t al. (21) studied the effect of a number of polyenoic
acids on SRS-A release from chopped sensitized guinea pig lung.
They found that some of the fatty acids such as arachidonic, 20:5
(5,8,11,14,17), 22:6 (4,7,10,13,16,19) and 18:3 (6,9,12) enhanced
SRS-A release while 20:3 (5,8,11), 20:3 (8,11,14). 20:2 (11,14),
20:3 (11,14,17). 18:3 (9,12,15) and oleic had no effect. They
concluded from their results that the latter fatty acids were not a
substrate for the lung lipoxygenase. These data are therefore in
disagreement with our results. However, it is very difficult to
interpret the study by Morris et aJL^ where whole lung tissue which
consists of a large number of dTfferent cells was utilized and fatty
acid uptake may vary with the cell types. Moreover, it is not clear
whether these exogenously added fatty acids were accessable to the
lipoxygenase,of the leukotriene pathway since no incorporation of
label from [ C]-arachidonic acid into SRS-A was achieved. Recently,
Hammerstrom and Samnuelsson presented evidence (22) that 20:5 (5,8,
11,14,17) and 20:3 (5,8,11) are converted by intact cells in the
presence of ionophore into leukotrienes.
A comparison of the known characteristics of the lipoxygenases
from platelets and RBL-1 cells, clearly shows that the two enzymes
are quite different. The lipoxygenase of the leukotriene pathway
(RBL-1) has a requirement for a 5, 8, 11 double bond and is stimu
lated by calcium (8). In contrast, the platelet lipoxygenase is
calcium" independent and no fatty acid specificity was apparent when
exposed to the same fatty acids that were tested on the leukotriene
pathway (ll).
The availability of a cell-free SRS generating system and
structural analogs will permit a continued elucidation of the enzy
matic and receptor recognition characteristics and the potential
evolution of potent enzyme or receptor antagonists for SRS and the
other leukotrienes.
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